Log in
Enquire now
Expres2ion Biotechnologies

Expres2ion Biotechnologies

Expres2ion Biotechnologies is a Danish company focused on delivering custom human, parasite, and viral proteins for applications in vaccine and therapeutics development.

OverviewStructured DataIssuesContributors

Contents

expres2ionbio.com
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Healthcare
Healthcare
Vaccine
Vaccine
Immunotherapy
Immunotherapy
Biomedical engineering
Biomedical engineering
Chemistry
Chemistry
Enzyme kinetics
Enzyme kinetics
Pharmacokinetics
Pharmacokinetics
...
Location
Hørsholm
Hørsholm
0
B2X
B2B
B2B
CEO
‌
Bent U. Frandsen
0
Founder
‌
Wian de Jongh
Date Incorporated
January 1, 2010
Email Address
info@expres2ionbio.com0
Phone Number
+45222210190
Full Address
Agern Allé 1, DK-2970 Horsholm, Denmark0
Place of Incorporation
Denmark
Denmark
Incorporation Reference
32770487
Founded Date
2010
Business Model
Licensing
Patents Assigned (Count)
1
Country
Denmark
Denmark
0

Other attributes

Company Operating Status
Active
Wikidata ID
Q96377541

Expres2ion Biotechnologies is a Danish company focused on delivering custom human, parasite, and viral proteins for applications in vaccine and therapeutics development. The company was incorporated in 2010.

Technology

Expres2ion Biotechnologies's primary technology platform is called ExpreS2, a non-viral insect (drosophila) cell expression system that establishes stable polyclonal pools that provide high protein expression levels without selection pressure. The company says its system is designed for transient or stable transfections using vector DNA containing a very strong proprietary hybrid promoter.

ExpreS2 uses embryonic drosophila melanogaster (fruit fly) cells, called S2 cells. S2 cell lines were first created by Imogene Schneider in 1972.

The company cites a number of key features of its protein expression platform:

  • Expresses complex proteins including heterodimers and other multimers
  • Expressed proteins are very homogenous
  • Easy to access more protein from original producing pool
  • Consistent expression through cloning
  • Very high cell density without aggregation or toxic metabolite buildup issues
  • Flexible under various culture and process conditions
  • Suitable for perfusion processes using established equipment
  • Reduced risk of human contaminants, compared to other systems in use

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

ExpreS2ion announces EU grant award for the COVID-19 vaccine development programme

https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-eu-grant-award-for-the-covid-19-vaccine-development-programme,c3054055

Web

March 6, 2020

References

Find more companies like Expres2ion Biotechnologies

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.